Shyam Patel

2 months ago | medium.com | Shyam Patel

Shyam Patel·Follow3 min read·--Leverage NASA’s website data scrapping for images by Rover on the surface of Mars. Finding areas for the presence of water on the surface of the planet. This project aims to analyze images of Mars to identify potential environments that could support life. Using various image processing techniques, we evaluated a large dataset of Mars images for features that might indicate habitable conditions or areas of scientific interest.

2 months ago | onclive.com | Shyam Patel

CommentaryVideoJanuary 31, 2025Author(s):Shyam A. Patel, MD, PhD, discusses secondary prevention strategies that may mitigate the risk of developing SPCs after receipt of CAR T-cell therapy.

2 months ago | onclive.com | Shyam Patel |Saurabh Dahiya

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’s episode, we had the pleasure of speaking with Saurabh Dahiya, MD, FACP, and Shyam A.

Dec 10, 2024 | onlinelibrary.wiley.com | Shyam Patel |Lachelle D. Weeks

Approximately a decade ago, clonal haematopoiesis (CH), caused by acquired mutations in genes associated with myeloid neoplasia (MN), was initially characterized as a common age-related condition associated with an increased risk for blood cancers such as myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).1 In CH, genetically related haematopoietic stem and progenitor cells (HSPCs) have a fitness advantage compared to normal HSPCs due to somatic mutations and make an outsized...

Sep 29, 2024 | nature.com | Shyam Patel

AbstractPatients with TP53 aberrations comprise the highest risk subset of all myeloid malignancies. The managerial conundrum of TP53-mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) stems from refractoriness to or relapse after conventional chemotherapy, as well as the limited translational success of investigational therapies targeting TP53-mutant cells. Thus far, no targeted therapies have been commercially approved for this mutational subset.